[Newsprime] C&R Research received ‘highest ever’ new orders last year, expected to turn profitable
‘Stocks’ is considered a hot keyword for investors who are unable to find suitable investments, including the MZ generation.
Accordingly, the industry is paying attention to C&R Research (359090), a specialized clinical trial trust agency that has a symbiotic relationship with pharmaceutical and bio new drug development. C&R Research, which holds the largest number of anticancer drug clinical trial references in Korea through differentiated competitiveness such as △IT capabilities △Full-scope clinical performance ability △global expansion, recorded cumulative sales of KRW 36.1 billion and sales of KRW 3.3 billion on a separate basis in the third quarter of last year. Net profit increased. This is an increase of 11.1% and 46.4%, respectively, compared to the same period last year. Lee Ji-hyun, a researcher at Mirae Asset Securities, said, “The company’s sales this year are expected to be about KRW 50 billion, up 16% from last year, and new orders are expected to be about KRW 70 billion, up 16% over the same period.” “It has been resolved,” he analyzed.
